Polymorphism | Men | Women | ||||||
Control n (%) | NSCLC n (%) | OR (95% CI) | p | Control n (%) | NSCLC n (%) | OR (95% CI) | p | |
VEGF −634C > G | n = 295 | n = 181 |
| n = 88 | n = 52 |
| ||
GG | 150 (50.9) | 94 (51.9) | 1.00 |
| 48 (54.5) | 24 (46.1) | 1.00 | 0.61 |
GC | 133 (45.1) | 70 (38.7) | 0.84 (0.57 - 1.24) | 0.05 | 35 (39.8) | 25 (48.1) | 1.43 (0.70 - 2.90) | |
CC | 12 (4.1) | 17 (9.4) | 2.26 (1.03 - 4.94) |
| 5 (5.7) | 3 (5.8) | 1.20 (0.26 - 5.45) | |
GC+CC | 145 (49.1) | 87 (48.1) | 0.96 (0.66 - 1.39) | 0.82 | 40 (45.5) | 28 (53.9) | 1.40 (0.70 - 2.79) | 0.34 |
VEGF −2578C > A | n = 295 | n = 181 |
| n = 88 | n = 52 |
| ||
CC | 65 (22.0) | 55 (30.4) | 1.00 | 0.13 | 23 (26.1) | 12 (23.1) | 1.00 | 0.89 |
CA | 159 (53.9) | 87 (48.1) | 0.65 (0.41 - 1.01) | 44 (50.0) | 28 (53.9) | 1.22 (0.52 - 2.84) | ||
AA | 71 (24.1) | 39 (21.6) | 0.65 (0.38 - 1.10) | 21 (23.9) | 12 (23.1) | 1.10 (0.40 - 2.96) | ||
CA+ AA | 230 (78.0) | 126 (69.6) | 0.65 (0.43 - 0.99) | 0.04 | 65 (73.9) | 40 (76.9) | 1.18 (0.53 - 2.63) | 0.69 |
VEGF +936C > T | n = 295 | n = 181 |
| n = 88 | n = 52 |
| ||
CC | 217 (73.6) | 125 (69.1) | 1.00 | 0.45 | 59 (67.0) | 33 (63.5) | 1.00 | 0.90 |
CT | 70 (23.7) | 48 (26.5) | 1.19 (0.78 - 1.83) | 24 (27.3) | 16 (30.8) | 1.19 (0.56 - 2.56) | ||
TT | 8 (2.7) | 8 (4.4) | 1.74 (0.64 - 4.74) | 5 (5.7) | 3 (5.8) | 1.07 (0.24 - 4.78) | ||
CT + TT | 78 (26.4) | 56 (30.9) | 1.25 (0.83 - 1.87) | 0.29 | 29 (33.0) | 19 (36.5) | 1.17 (0.57 - 2.40) | 0.67 |